News | December 27, 2022
Hetero's COVID-19 oral drug gets WHO prequalification
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
The organisation is also working towards providing skills based training programmes to the workers for paramedical jobs and has launched certificate courses in ten disciplines
Centre and states need to work in tandem and in a collaborative spirit as was done during the previous surges for COVID-19 prevention and management
Miravo to remain a Canadian controlled and operated company following closing of the transaction
Modi stressed the need to ensure that the entire Covid infrastructure at all levels is maintained at a high level of preparedness in terms of equipment, processes, and human resources
The expansion in Indore is well-aligned with Lupin Diagnostics’ commitment to improving access to high-quality, reliable, and advanced testing centres and home collection facilities at an affordable price
This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation
As per the agreement, NSE-listed Vaishali Pharma Limited will take over the entire domestic and international marketing of Jark Pharma’s portfolio of quality based ayurvedic products
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
Subscribe To Our Newsletter & Stay Updated
